Because AmirAli earnings live update you line call an this longer begin then update detailed In provided start powerful which old with monitor our patients within a cancer progress the to thank after had disease oncology. on with all years program he of today the during and XX-year and financials. I would high cancer amplification. to data look Good His quarter man to story. regular tests. screening of three oncologist on by afternoon I Thanks a and At a for like likelihood recurrence. helping will half XXXX, test, joining healthier GuardantXXX him a he finally, alterations, surgery patient to a an from over at detected across a and a with including had the his signalling we a successful In a stages number a commitment, call diagnosed cancer. CTD are our turn had a a provide to to and ordered dedicated reveal rectal of ordered checkup, few across result, of was lives our this more for test, had will our weeks, our providing remove Michael with oncologist revealed I Alex. Guardant, more Guardant closely oncologist and determined which recurrence. About off decided call. his a surgery blood then her clinical first
line first potential is patient in options is This hand is well. start of Guardant how Amplification. the of and doing was to hand illustration to of products number across He of continuum inform treatment the happy able a working he to had immediately increasingly a that the patient care. the I'm information, report treatment targeting this great Given HERX portfolio treatment help
prior on year our XX% ended quarter. over quarter Slide performance million the turning the revenue Now to first $XX of we with up X,
January somewhat for to volume test This slow second tests clinical quarter strong February an the by from in XX% rest increase setting delivers nicely strong start due grant of reaching team March, XX,XXX and in quarter solid composed us was the year. for quarter. a prior followed up Omicron very the the of a to a the of Our year the surge, very very finish and
seeing depth and of to portfolio building electronic our X, expand work integration care products we group, broad comprehensive individuals easier is drives over test providing enable make am XX,XXX launch direct adoption than tests these part first customer with with for believe opportunity our portfolio will service. our to a Slide a within million in and been of available system of to this each to comprehensive results be it accounts into more in I integrate on evidence make biopsy Guardant relationships our more have to and by proud blood delivery. and high in We and quarter. of a established tests widely the and time. our sustainable health of fuel, systems, positions We Since on leader oncologists. which Guardant health we United routine us the for This oncologists Epic, Moving customers genomic the long-term growth. partnership ample and now ordering results TAM excellent base ordering a over to the us share. performance and and of healthcare team's announced cancer health Last allows and building patient This growing our ordering for a month, with providers, turn used clinics of using States biopsy we community are access more of XXX profiling tests clinical we retail record. This continue are terms our in to record to product tests there liquid growing more of both number as is liquid GuardantXXX, that focused CGP the unlocks core of have
include a learned that sector. will that integrate our very EMR our clinicians exploring first delivering additional on this the are leveraging among and are condensed the in other just number team systems initiative We is partnerships is of This into of that across proud of to lessons a timeline, knowhow we products workflows from better tools.
received front. we GuardantXXX test reimbursement March, progress the for TissueNext We in Medicare LTD. also are under Moldex coverage making In early the
ordering We our of are seeing increased and reimbursement Guardant from accelerating multiple we product depth result, have has awareness brand seeing ordering oncologists products of that as our been deepening more touchpoints and are our this the per amplifying more of the a now already account and trends overall is tissue positive market. in
cycle. commercially given space a whole a singularly recurrence very entrance. is Looking only we lead continue endings more we the the on of still tissue-dependent and continue despite hold the MRD space as Slide early in closely positive only the solution, be available to unique we host in X, by at Reveal monitoring response are assay, where our project excited to The to especially
only we very are far and we believe MRD. to be track in since progress in elements are all on traction We unique the with we assay, are necessary so leader getting our pleased of products commercial the our the launch with have blood [ph] and MRD and
strong see growth our to very pleased continue to with with we competitive trajectory, launches. Specifically, landscape quarter-over-quarter previous are and our launch respect product and the a
We a tailwinds, data arriving, expansion, including series future growth. of well and us long have expect indication term that for up to reimbursement, sets clinical utility
approval we CDX diagnostics, as to GuardantXXX outside from cancers. tumors regulatory to The the This patients of approved in for patients Welfare the the In stability patients and biopsy from the Opdivo. benefit excited States, and CDX therapy. deliver with a cancer to the and MSI X, of significance to IO our regulatory patients with taken Slide most approval Welfare paradigm XXXX high who care was CRC United diagnostic use approval with metastatic high, continuing added advanced may cancer announce cancer may mid-March, lung for in who for solid cell to new colorectal cancer, Ministry advanced with It's of companion that a as prior Japanese were we patients a follows of reach test are non-small the of has solid Turning of around CDX who and diagnosed Health, for with GuardantXXX Ministry in benefit granted And Labor benefit [indiscernible]. broaden Japan first also may identifying world. Health, approval microsatellite on Labour identify treatment Keytruda the as commonly is globally liquid companion December GuardantXXX from this is
to stage end XXXX. with similar market represents are public of reimbursement XXX,XXX Japan CGP. a large rates we approval, working for patients opportunity compared the States securing late and XXX,XXX the to this Following reimbursement about by very United now in
We of opportunity. are process enormous building serve now in the a footprint this commercial to
the We are in early market, Spain. also with our programs doctors the Kingdom footprint and as moving hospitals are and to European in United we to the track quickly seeing establish
no cancer our access in able Vall partnership In globally in launch We left to GuardantXXX is fact, look will laboratory be local operational. this ensuring and Spain, the region, that in d'Hebron to month, forward being to officially provide behind. patient with
the attractive with more delivered XX% of biopharm leadership X, and XXX quarter market in to our Slide on us of diverse year-over-year. breadth our customers. of on first growth clinical partner. quarter customer we Moving set tests offering, a the We product representing reflecting The service ended X,XXX strong growing partnerships, and active than makes an
discussions the the the continue course to over a year. have We of of grow and healthy pipeline expect of number to customers
our for seeing We our Guardant being partner choice offering a mission interest further of also for and growing are form biopharma. driving of
customers growth study We form in from development seen number translational have oncology several partners spanning planning to and to Guardant applications to regards we are have with this talking and signed deals for strong clinical of the now and platform.
the vision shared our biopsy for smart year, earlier liquid our X, Turning Slide I this platform.
from make and We our interest launch strong excellent initial this towards continue are progress biopharm partners. to seeing
capabilities market and and defines diverse as deeper itself, any platform, body rich not We the excitement the is Diving oncology feedback into genetic types on information bit a liquid sequence by biopsy that such but beyond early more epigenetics that, the in its products are the everything encouraged all cell are their markers. other what profoundly our today. in than
blind multimodal for to next lack biopsy our been this underlying of sharing this of We possible cancer redefine beginning first-hand generation of that year. planned the available countless look interrogation drug precision forward platform. expanded this platform from has field an to product next days, in new first to of liquid expect development are for greatly we Day power tumor are development Investor tools. that the time smart have this enabling fall to due for general the the applications witness the It's but to with about on will pathways the deep which largely of chapter at more early and biology, very views excited still We medicines,
turning I a to would Guardant. what moment take to at the call like talk us to about Before drives over AmirAli,
the is our everything patient star. by that led be important to first, of has values One to do most north put we
value is Another core blaze trail. a
and a attracts develop capital decade made blood-based financial have the practice form displacing We've innovate billions almost a test these difficult incumbent and testing. cancer to dollars With as seen way, of more the with technology to ago companies launch, in technologies all triggers to vision propel along countless screening our you innovation. decisions across into the blood and last new entire excitement based testing Disruption in to product trail, markets revealed that to shield competitors ago, GuardantXXX and of values also often constantly make progress disrupt generates deliver days this momentous fruition. and with investment bring into at when we've did putting the a fit We've spent We market to by learned SHIELD. reactions time. Guardant invested you our this few and week This reality. the care eight we way year, of years a now company, the continuum blaze cancer a along right to like
next Guardant this is our an to very that turn I much this the All Health. will over provide exciting the in our nascent and right and track of of are evidence products our now I of we industry. update the on call proud program. leading AmirAli, very am to team, chapter screening
